Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
